PR98448

MOUNTAIN VIEW, Calif., Oct. 25, 2022 /PRNewswire=KYODO JBN/ --

- Preclinical data showing how ERA(TM), eTurna(TM) technologies turbocharge

T-cell therapies presented at New Frontiers of RNA Nanotherapeutics meeting

today

- ERA(TM) boosts CAR T-cell efficacy by overcoming T-cell exhaustion that

inhibits cancer cures

- eTurna(TM) delivery platform delivers more healthy, functional T-cells than

electroporation, without the safety risks of viral vectors

- Use of both technologies has the potential to lower cost of T-cell therapies,

expand patient access

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA

medicines to cure untreatable, age-related conditions, today presents interim

pre-clinical data that demonstrates treating T cells with its proprietary

technologies can significantly increase their ability to kill cancer.

Photo - https://mma.prnewswire.com/media/1927460/GettyImages_1227506537.jpg

The data show that using Turn Bio's Epigenetic Reprogramming of Aging (ERA(TM))

technology and its eTurna(TM) delivery platform in the manufacture of T cells

can produce and deliver more effective therapies more efficiently. The findings

promise to help reduce the cost of T-cell therapies and make them more

accessible to cancer patients.

"Our data show that using ERA technology and our eTurna delivery platform can

overcome the fundamental problem of T-cell exhaustion and aging that limit the

efficacy and long-term effectiveness of CAR-T therapies," said Vittorio

Sebastiano, company co-founder and head of research. "ERA provides the

opportunity for enhanced dose management and optimization with the ability to

personalize dosing to maximize efficiency without compromising patient safety.

"We found eTurna preserves T-cell health and functionality better than

electroporation, facilitating greater cell viability and production during CAR

T manufacturing," he said. "It also provides superior safety compared to viral

gene delivery, thus mitigating many manufacturing, biological and regulatory

challenges."

Sebastiano's presentation, "First Look Data: Epigenetic Reprogramming of Aging

(ERA) – A New Paradigm in Cell Rejuvenation," takes place at New Frontiers of

RNA Nanotherapeutics, at 10 a.m. CST at Houston Methodist Research Institute.

Turn Bio's technologies were applied concurrently with the CAR T-cell

manufacturing process, which demonstrates that T-cell immunotherapy products

can be enhanced without additional time or facilities beyond those already

needed for manufacturing.

The company's process can transfect immune cells with rates as high as

industry-standard electroporation, but with no cytotoxicity. The eTurna

Platform(TM) was used to precisely control timing, duration and activation of

the ERA factor cocktail while preserving cellular identity.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the

cellular level and developing transformative drug delivery systems. The

company's proprietary mRNA platform technology, ERA(TM), restores optimal gene

expression by combatting the effects of aging in the epigenome. This restores

cells' ability to prevent or treat disease and heal or regenerate tissue. Its

eTurna(TM) Delivery Platform uses unique formulations to precisely deliver

cargo to specific organs, tissues and cell types.

The company is completing pre-clinical research on tailored therapies targeting

indications in dermatology and immunology, and developing therapies for

ophthalmology, osteo-arthritis and the muscular system. For more information,

see http://www.turn.bio.

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup

jim@rightstorygroup.com or (312) 543-9026

SOURCE Turn Biotechnologies, Inc.